IDT written submission to The Government, page-2

NOVAVAX IS IN TALK WITH LOCAL MANUFACTURER(S) !!!

What about Novavax?

According to Professor Cunningham, Novavax "looks good", with recent trial results showing the vaccine offered 100 per cent protection against severe COVID-19 disease and an 86.3 per cent efficacy against the UK variant.
Australia has an agreement for 51 million doses of Novavax, originally slated for "mid-2021".
In the UK, Novavax will be manufactured locally. But in Australia it will need to be imported because of a lack of capable vaccine manufacturers.
However, the ABC understands Novavax has been in early-stage talks with Australia's biopharmaceutical sector to explore options to outsource some of its supply locally.
The company told the ABC it would "continue to move forward as aggressively as possible to deliver a safe and effective vaccine to end the pandemic".
"We already have an advance purchase agreement in place with Australia and we continue to work toward finalising our regulatory submissions," the company said.
ATAGI and Australia's COVID vaccines


Who are the experts who have caused Prime Minister Scott Morrison to change Australia's approach to the COVID-19 vaccine rollout and why did they do so?
Read more
Professor Kelly said the TGA did not have the "final components" of Novavax's clinical trials yet.
"But when we do, the TGA, as it did with the other two vaccines we have been using in the last couple of months will absolutely expedite that matter and as soon as Novavax is ready to supply to Australia we will be going through those processes," he said.
Looking to the year ahead, Professor Cunningham said it was important to remember that the health advice from ATAGI could change as more information regarding the AstraZeneca vaccine came to light.
"We may be able to pin down the decision around this side-effect," he said.
"There's a lot of uncertainty about who's at risk; firstly it's young women and now it's young people, [so] this advice is likely to change again.
"But I think the one thing that really stood out for ATAGI was the 25 per cent mortality rate.
"No-one could have anticipated this. But the lesson learnt over this whole pandemic is the important sovereign vaccine production, in future we need the capability to produce MRNA vaccines in Australia."